688235:SHA
BeOne Medicines AG
CN¥275.00
arrow_downward
-0.10%(-0.28) 1D
Nov 17, 3:00:02 PM GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CN¥273.01
High
CN¥277.87
Low
CN¥269.30
Mkt. cap
334.34B
Avg. vol.
3.51M
Volume
2.54M
P/E ratio
66.16
52-wk high
CN¥319.24
52-wk low
CN¥205.51
EPS
CN¥4.16
No. of employees
12K
Open
CN¥273.01
High
CN¥277.87
Low
CN¥269.30
Mkt. cap
334.34B
Avg. vol.
3.51M
Volume
2.54M
P/E ratio
66.16
52-wk high
CN¥319.24
52-wk low
CN¥205.51
EPS
CN¥4.16
No. of employees
12K
News stories
From web sources and news partners
Investing.com
·
4 hours ago
Jefferies reiterates Buy on BeOne Medicines stock, $470 target
Investing.com
·
7 hours ago
BeOne Medicines expands CLL Society partnership to $3 million
Investing.com
·
7 hours ago
BeOne Medicines at Jefferies: oncology shift broadens beyond BRUKINSA
marketscreener.com
·
18 hours ago
BeOne Medicines to Invest $19.5 Million in Bravera Bio Series A Financing
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeonemedicines.com